Clinics warned of fines for promising full recovery in advertising
The Competition Promotion and Consumer Protection Committee has warned medical organizations of liability for advertising that promises guaranteed treatment results or the absence of side effects. Such violations are punishable by a fine of 70 BCV.
According to the regulator, promotions of medical services have recently often included phrasing such as "cure the disease forever," "heal in three days," "completely safe," and claims that there are no side effects. The agency reminded that Article 16 of the Law "On Advertising" prohibits phrasing that misleads consumers, denies contraindications, or guarantees recovery. Organizations are also prohibited from advertising areas of practice not specified in their license.
Improper advertising is punishable by a fine of 70 BCV, and any damage caused to the consumer must be reimbursed in full. The agency stated that it will continue systematic monitoring of advertising materials.
The warning followed a rise in complaints: since the beginning of 2026, the committee has registered over 900 appeals in the medical and pharmaceutical sectors, which is nearly double the figure for the same period last year. Following their review, clients received recalculations of over 300 million soums for goods and services. At the same time, the agency did not provide the exact share of complaints related directly to advertising.
What it means
Medical clinics face fines of 70 BCV for misleading pledges in advertising and promoting services outside their license, along with an obligation to compensate clients in full for any damage caused.
Sources
- Anhor.uz: Комитет предупредил клиники о штрафах за обещания гарантированного лечения media outlet
- Nuz.uz: «Вылечим за 3 дня»: клиникам в Узбекистане грозит штраф за рекламу с обещаниями media outlet
This article was prepared with the help of AI and translated from the Russian original. Spotted an error — let us know.
Published 21 September 2026, 12:16 · No updates · Russian original




Discuss the news in our Telegram channel. Subscribe